Research Insights Despite semaglutides proven efficacy in diabetes and obesity treatment, there is significant heterogeneity in weight loss experienced by patients and genetic factors remain unclear
Kasia Lipska, MD, MHS, BS Associate Professor of Medicine, Endocrinology and Metabolism Putting older adults at the center of the story opens up a new frontier in obesity research, Lipska adds
After stopping the drugs, people experience a return of cravings and hunger, and most people in clinical trials gain back 50 percent of weight lost in 12 to 18 months. These Drugs Are Part of a Long-Term Solution Because of the risk of rebound weight gain after stopping semaglutide, people prescribed Wegovy for obesity may need to take the drug for the rest of their lives
Youll be surprised by which stars GLP-1 reveal was followed by the biggest spike in appointments See more of our coverage in your search results
Additionally, it helps lower the chances of serious heart-related issues like heart attacks, strokes and cardiovascular death in adults who already have heart disease and are either obese or overweight